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Abstract 
Stromal tumors of the prostate are rare and
only a few cases have been described in the lit-
erature, including exceptional cases of stromal
tumors  with  unknown  malignant  potential
(STUMP) and a fatal outcome in young patients.
Morphologically distinguishing a STUMP from a
stromal sarcoma of the prostate (PSS) is still a
challenge. We describe the histopathological and
immunohistochemical findings in a 34-year-old
man with a malignant specialized cell stromal
tumor of the prostate that was diagnosed initial-
ly as STUMP, and he developed lung metastases
within a few months. The patient attended our
hospital because of lower urinary tract symp-
toms, after having excreted tissue through the
urethra a few months before. Ultrasonography
and urethrocystoscopy examinations showed a
mass  arising  from  the  verumontanum,  and  a
transurethral resection (TUR) revealed a high-
grade spindle cell sarcoma reminiscent of a phyl-
lode tumor of the breast. The tumor cells were
immunoreactive  for  vimentin,  progesterone
receptor  and,  focally,  CD34.  The  preliminary
histo  logical  findings  were  subsequently  con-
firmed after radical prostatectomy. The patient
developed bilateral lung metastases and died 25
months after the initial diagnosis. Although rare
in young patients, the challenging differential
diagnosis  of  STUMP  and  PSS  means  that  a
prostate STUMP diagnosis made on the basis of
biopsy or TUR specimens also requires urethro-
cystoscopic monitoring for the early detection of
any progression to PSS. Radical prostatectomy
should also be carefully considered.
Introduction
Stromal tumors of the prostate are rare and
arise  from  specialized  hormone-dependent
mesenchymal cells.
1 They have a broad spec-
trum of histological features and, depending
on parameters such as cellularity, the number
of mitotic figures, necrosis, and the stromal
infiltration of periprostatic tissues, are classi-
fied as phyllode tumors of the prostate, various
subtypes of stromal tumors of uncertain malig-
nant potential (STUMP), or prostatic stromal
sarcomas (PSS).
2,3 PSS have an immunohisto-
chemical profile that distinguishes them from
other prostate sarcomas such as leiomyosarco-
mas or rhabdomyosarcomas.
4 Although some
tumors seem to arise centrally near the veru-
montanum, most develop in the posterior por-
tion of the gland.
2,5 The patients may be young
and  typically  present  with  acute  or  chronic
urin  ary  obstruction,  and  possibly  hematuria
and  dysuria.  The  tumors  cause  well-known
local  morbidity,  but  their  management  and
prognosis are still uncertain.
1,2,5
We describe the case of a patient in whom
an initial diagnosis of STUMP was made on
the basis of tissue excreted through the ur  -
ethra, but rapid local recurrence and multiple
pulmonary  metastases  suggested  a  highly
malignant PSS. We also review the literature
concerning  stromal  tumors  diagnosed  in
young patients.
Case Report
This 34-year-old man developed progressive
urinary  obstruction  in  September  2007.  The
findings of an ultrasound examination were
unremarkable, but intravenous urography and
cystography performed elsewhere showed an
oval mass within the lumen of the prostatic
urethra (Figure 1). The day before he was hos-
pitalized for further tests, the patient observed
pieces  of  tissue  during  micturition,  one  of
which  was  available  for  histopathological
examination and led to a diagnosis of prostat-
ic STUMP. The obstructive symptoms resolved
following tissue voiding and no treatment was
given. 
The  patient  first  attended  our  hospital
(IRCCS Istituto Clinico Humanitas - Rozzano,
Milan, Italy) four months later, when the symp-
toms  recurred.  Urethrocystoscopy  revealed  a
multi-lobed  mass  arising  from  the  verumon-
tanum, and so a transurethral resection (TUR)
was  performed.  Abdominal  computed  tomog  -
raphy (CT) and chest radiography did not reveal
any distant metastases. An endoscopic evalu  -
ation repeated seven months after the initial
diagnosis highlighted a local recurrence, which
was again treated by means of TUR. Histological
investigation confirmed the persistence of the
tumor and the patient underwent radical prosta-
tectomy (RP). As the tumor was near the surgi-
cal  margins  in  the  periprostatic  soft  tissue,
radiotherapy (60 Gy in 30 daily fractions) was
delivered to the prostate bed.
Despite  this  local  treatment,  12  months
after the first diagnosis and four months after
RP, CT revealed multiple metastatic nodules in
both lungs, whereas the abdomen and pelvis
showed no signs of neoplastic disease. After
discussion  in  the  multidisciplinary  sarcoma
unit and considering the well performance sta-
tus, the patient underwent lung metastasec  -
tomy,  which  revealed  a  high-grade  polymor-
phic sarcoma whose features recalled the pri-
mary prostatic sarcoma. 
In  February  2009,  the  patient  experienced
lung  and  pleural  progression,  and  pelvic
involvement was diagnosed by means of mag-
netic resonance imaging. The lung lesions par-
tially  responded  to  palliative  chemotherapy
with ifosfamide and liposomal doxorubicin, but
the pelvis disease progressed symptomatically.
Although  he  was  subsequently  administered
palliative radiotherapy to the left iliac region,
the patient died because of disease progression
25 months after the initial diagnosis.
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Pathology
Microscopically, the histological specimens
taken after both TURs showed a uniform prolif-
eration  of  spindle  and  ovoid  stromal  cells,
some of which had atypical nuclei, scattered
mitotic figures, and necrotic foci. A malignant
stromal tumor of the prostate was diagnosed.
After RP, the cut surface of the prostate showed
a gray-white polypoid mass protruding into the
urethral  lumen  with  numerous  hemorrhagic
foci (Figure 2), and histological examination
revealed  a  highly  malignant  mesenchymal
neoplasm with multiple areas of necrosis, high
mitotic count, and nuclear atypia (Figure 3A).
The spindle cell component was intercalated by
dilated epithelial structures reminiscent of a
malignant  phyllode  tumor  (Figure  3B),  and
there  were  tumoral  vessels  permeating  the
capsule and pericapsular tissue (Figure 3C).
Immunohistochemistry  findings  showed  that
the tumoral cells were reactive for vimentin
(Figure 3D), progesterone receptor (scattered
cells), and CD34. The margins were free, in
close proximity to foci of the tumor in peripros  -
tatic  soft  tissue.  The  final  histopathological
diagnosis was high-grade prostatic specialized
stromal sarcoma.
Discussion
It  is  not  difficult  to  distinguish  a  benign
stromal lesion from sarcoma of the prostate on
the basis of the detection of atypical stromal
cells, high cellularity, and invasion but the cor-
rect diagnosis of borderline lesions remains a
challenge and has led to the introduction of
terms such as “unknown malignant potential”
and “low malignant potential”. Gaudin et al.
identified  four  distinct  STUMP  subtypes
depending on their histological pattern and the
degree of atypia: hypercellular, myxoid, with
degenerative  atypia,  and  phyllode-like.
5 The
histological features of the relatively common
phyllode-like  subtype  have  recently  been
reviewed and may be similar to those of its
counterpart in the breast.
1Transformation may
occur,  but  always  after  several  local  recur-
rences.
Our case is notable because of its unusual
clinical presentation and the treatment dilem-
ma posed during disease progression. To the
best  of  our  knowledge,  there  are  only  two
reported cases of sarcoma diagnosed on the
basis of tumor tissue excreted through the ure-
thra: the first was a pediatric prostatic rhab-
domyosarcoma  and  the  second  a  high-grade
stromal sarcoma in a young adult which, as in
our case, showed widespread distant metas-
tases a few months after diagnosis.
6,7
A  review  of  the  literature  based  on  a
PubMed search for patients aged less than 40
years with a diagnosis of PSS, STUMP, PSS-PT,
or  STUMP-PT  identified  21  cases  described
since 1977, about 15-20% of all of the stromal
tumors reported worldwide (Table 1).
1-6,8-21 This
means that STUMP and PSS have been diag-
nosed in 10 and 11 cases, respectively. Five of
the patients with STUMP underwent RP, four
enucleation,  and  one  partial  prostatectomy
(PP), all of whom showed no signs of disease
after a median follow-up of 27 months (range:
1-36 months). Nine of the 11 patients with PSS
underwent RP, one TUR, and one multi-organ
exenteration; five received chemotherapy and
one radiotherapy after surgery. Four of these
11 patients (three of whom developed metas-
tases) died as a result of the PSS after a me  -
dian  follow-up  of  12  months  (range:  3-25
months); one patient was alive with metastat-
ic disease after 26 months; and seven showed
no signs of disease a median of 14 months
after  surgery  (range:  1-300  months).
Furthermore, the phyllode tumor pattern docu-
mented  in  five  patients  (four  PSS  and  one
STUMP)  did  not  seem  to  be  related  to  an
adverse clinical outcome.
Although not exhaustive because of the rar-
ity of the neoplasm, these data suggest that a
clear sarcomatous transformation leads to an
increased incidence of metastases and death;
however,  as  10  patients  with  STUMP  were
alive and without disease during follow-up, it
can be hypothesized that such tumors are cur-
able  surgically  in  the  majority  of  young
patients  and  have  a  benign/very  low  grade
Case Report
Figure  1.  Intravenous  urogram  showing
the tumor invading the prostatic urethra as
a contrast-defective oval mass within the
lumen.
Figure 3. (A) Malignant stromal cell prolif-
eration with necrosis and areas of high cel-
lularity (magnification: 100X). (B) Some
areas  of  the  tumor  with  cleft-like  spaces
lined  by  normal-looking  epithelial  cells
producing  a  leaf-like  (phyllode)  pattern
(magnification: 100X). (C) Radical prosta-
tectomy revealed the neoplastic invasion of
blood vessels in the capsular region of the
prostate  (magnification:  100X).  (D)
Neoplastic  cells  immunoreactive  for
vimentin demonstrating the mesenchymal
origin of the tumor (magnification: 200X).
Figure 2. Whole prostate section. The cut
surface  shows  a  gray-white  hemorrhagic
polypoid  mass  originating  from  the
peripheral zone of the gland, which com-
pletely  occluded  the  urethral  space  and
infiltrated the extra-prostatic tissue.
A
B
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malignant course. As the name indicates, the
malignant  potential  of  STUMPs  is  unclear:
some grow slowly (if at all) over a period of
several  years  whereas  others  infiltrate  the
prostate extensively, invade adjacent rectal tis-
sue, and often develop recurrences after sur-
gery.
1,2,5,22 Some  STUMPs  may  dedifferentiate
and  progress  to  PSS,
2,5,15,19,23 generally  over
years; in other cases STUMP and PSS may be
present in the same tissue specimens as sep  -
arate foci or merging into each other. 
It may not be possible to determine whether
a neoplastic lesion is malignant or not on the
basis  of  biopsy  or  TUR  samples  because  of
sampling  problems.  In  the  case  of  biopsy
mater  ial,  some  authors  have  recommended
the  use  of  the  term  “uncertain  malignant
potential” in cases that do not satisfy the tradi-
tional  criteria  of  malignancy:  for  instance,
marked  cellularity,  a  high  degree  of  mitotic
activity, nuclear atypia, necrosis, or extracap-
sular  invasion;
5 however,  others  claim  that
classifying  a  tumor  as  stromal  proliferation
with unknown malignant potential might only
confuse urologists and therefore not be very
helpful. Herawi and Epstein found that seven
(14%) of the 50 stromal tumors of the prostate
they analyzed were STUMPs associated with
sarcoma:  three  of  these  patients  developed
metastases during follow-up while there was
no evidence of disease in the remaining four
patients, thus demonstrating that only the his-
tological subtypes of STUMP harboring foci of
sarcoma do not correlate with clinical behav-
ior.
2
It is possible that this was true in our case.
After  the  first  recurrence  in  which  a  small
focus of clear high-grade sarcoma was detect-
ed, the patient underwent RP and the speci-
men  showed  locally  advanced  disease  –
although rapidly implemented, this aggressive
treatment  failed  to  control  the  disease,  and
multiple  bilateral  lung  metastases  developed
within  a  few  months.  We  conclude  that  all
cases of STUMP should be closely monitored
clinically by means of both imaging and ur  -
ethroscopy in order to be able to identify any
progression  to  PSS  early,  and  that  radical
prostatectomy should be carefully considered
as well in young patients even if only a focal
area of high-grade stromal sarcoma is found in
TUR material.
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